Dynamic balance of multiple myeloma clonogenic side population cell percentages controlled by environmental conditions

International Journal of Cancer

Volumn 136, Issue 5, 2015, Pages 991-1002

  Wen, Jianguo ^a   Tao, Wenjing ^b   Kuiatse, Isere ^b   Lin, Pei ^b   Feng, Yongdong ^c   Jones, Richard J ^b   Orlowski, Robert Z ^b   Zu, Youli ^a  

^a HOUSTON METHODIST HOSPITAL   (United States)

^b UNIVERSITY OF TEXAS   (United States)

^c HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

Cancer stem cells; Environmental factors; Multiple myeloma; Side population

Indexed keywords

CD20 ANTIGEN; SYNDECAN 1; MESSENGER RNA; TRANSFORMING GROWTH FACTOR BETA1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER STEM CELL; CARCINOGENICITY; CELL CLONE; CELL DIFFERENTIATION; CELL HYPOXIA; CLINICAL ARTICLE; CONTROLLED STUDY; HUMAN; HUMAN CELL; MOUSE; MULTIPLE MYELOMA; MULTIPLE MYELOMA CELL LINE; NONHUMAN; SIDE POPULATION CELL; SIGNAL TRANSDUCTION; ANIMAL; ANOXIA; ENVIRONMENT; ENZYME IMMUNOASSAY; GENETICS; METABOLISM; NONOBESE DIABETIC MOUSE; PATHOLOGY; PATHOPHYSIOLOGY; PHENOTYPE; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SCID MOUSE; TUMOR CELL CULTURE;

ANIMALS; ANOXIA; CELL DIFFERENTIATION; ENVIRONMENT; IMMUNOENZYME TECHNIQUES; MICE; MICE, INBRED NOD; MICE, SCID; MULTIPLE MYELOMA; NEOPLASTIC STEM CELLS; PHENOTYPE; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SIDE-POPULATION CELLS; SIGNAL TRANSDUCTION; TRANSFORMING GROWTH FACTOR BETA1; TUMOR CELLS, CULTURED;

EID: 84918785171     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.29078     Document Type: Article

References (48)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2007. CA Cancer J Clin 2007;57:43-66.
2. Cruz RD, Tricot G, Zangari M, et al. Progress in myeloma stem cells. Am J Blood Res 2011;1:135-45.
3. Pozzi S, Marcheselli L, Bari A, et al. Survival of multiple myeloma patients in the era of novel therapies confirms the improvement in patients younger than 75 years: a population-based analysis. Br J Haematol 2013;163:40-6.
4. Matsui W, Wang Q, Barber JP, et al. Clonogenic multiple myeloma progenitors, stem cell properties, and drug resistance. Cancer Res 2008;68:190-7.
5. Yang Y, Shi J, Tolomelli G, et al. RARalpha2 expression confers myeloma stem cell features. Blood 2013;122:1437-47.
6. Arima Y, Hayashi N, Hayashi H, et al. Loss of p16 expression is associated with the stem cell characteristics of surface markers and therapeutic resistance in estrogen receptor-negative breast cancer. Int J Cancer 2012;130:2568-79.
7. Jakubikova J, Adamia S, Kost-Alimova M, et al. Lenalidomide targets clonogenic side population in multiple myeloma: pathophysiologic and clinical implications. Blood 2011;117:4409-19.
8. Kotoucek PP, Orfao A. Myeloma stem cell concepts, heterogeneity and plasticity of multiple myeloma. Br J Haematol, in press.
9. Bonnet D, Dick JE. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med 1997;3:730-7.
10. O'Brien CA, Pollett A, Gallinger S, et al. A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature 2007;445:106-10.
11. Chiron D, Surget S, Maiga S, et al. The peripheral CD1381 population but not the CD138-population contains myeloma clonogenic cells in plasma cell leukaemia patients. Br J Haematol 2012;156:679-83.
12. Trepel M, Martens V, Doll C, et al. Phenotypic detection of clonotypic B cells in multiple myeloma by specific immunoglobulin ligands reveals their rarity in multiple myeloma. PLoS One 2012;7:e31998.
13. Hajek R, Okubote SA, Svachova H. Myeloma stem cell concepts, heterogeneity and plasticity of multiple myeloma. Br J Haematol 2013;163:551-64.
14. Matsui W, Huff CA, Wang Q, et al. Characterization of clonogenic multiple myeloma cells. Blood 2004;103:2332-6.
15. Kim D, Park CY, Medeiros BC, et al. CD19-CD45 low/-CD38 high/CD1381 plasma cells enrich for human tumorigenic myeloma cells. Leukemia 2012;26:2530-7.
16. Ho MM, Ng AV, Lam S, et al. Side population in human lung cancer cell lines and tumors is enriched with stem-like cancer cells. Cancer Res 2007;67:4827-33.
17. Szotek PP, Pieretti-Vanmarcke R, Masiakos PT, et al. Ovarian cancer side population defines cells with stem cell-like characteristics and Mullerian Inhibiting Substance responsiveness. Proc Natl Acad Sci USA 2006;103:11154-9.
18. Ikegame A, Ozaki S, Tsuji D, et al. Small molecule antibody targeting HLA class I inhibits myeloma cancer stem cells by repressing pluripotency-associated transcription factors. Leukemia 2012;26:2124-34.
19. Nara M, Teshima K, Watanabe A, et al. Bortezomib reduces the tumorigenicity of multiple myeloma via downregulation of upregulated targets in clonogenic side population cells. PLoS One 2013;8:e56954.
20. Wen J, Feng Y, Bjorklund CC, et al. Luteinizing Hormone-Releasing Hormone (LHRH)-I antagonist cetrorelix inhibits myeloma cell growth in vitro and in vivo. Mol Cancer Ther 2011;10:148-58.
21. Wen J, Feng Y, Huang W, et al. Enhanced antimyeloma cytotoxicity by the combination of arsenic trioxide and bortezomib is further potentiated by p38 MAPK inhibition. Leuk Res 2010;34:85-92.
22. Goodell MA, Brose K, Paradis G, et al. Isolation and functional properties of murine hematopoietic stem cells that are replicating in vivo. J Exp Med 1996;183:1797-806.
23. Kummalue T, Chuphrom A, Sukpanichanant S, et al. Detection of monoclonal immunoglobulin heavy chain gene rearrangement (FR3) in Thai malignant lymphoma by High Resolution Melting curve analysis. Diagn Pathol 2010;5:31.
24. Van Krieken JH, Langerak AW, Macintyre EA, et al. Improved reliability of lymphoma diagnostics via PCR-based clonality testing: report of the BIOMED-2 Concerted Action BHM4-CT98-3936. Leukemia 2007;21:201-6.
25. Burack WR, Laughlin TS, Friedberg JW, et al. PCR assays detect B-lymphocyte clonality in formalin-fixed, paraffin-embedded specimens of classical hodgkin lymphoma without microdissection. Am J Clin Pathol 2010;134:104-11.
26. Wen J, Cheng HY, Feng Y, et al. P38 MAPK inhibition enhancing ATO-induced cytotoxicity against multiple myeloma cells. Br J Haematol 2008;140:169-80.
27. Kumar SM, Liu S, Lu H, et al. Acquired cancer stem cell phenotypes through Oct4-mediated dedifferentiation. Oncogene 2012;31:4898-911.
28. Azab AK, Hu J, Quang P, et al. Hypoxia promotes dissemination of multiple myeloma through acquisition of epithelial to mesenchymal transition-like features. Blood 2012;119:5782-94.
29. Martin SK, Diamond P, Gronthos S, et al. The emerging role of hypoxia, HIF-1 and HIF-2 in multiple myeloma. Leukemia 2011;25:1533-42.
30. Zhang H, Wu H, Zheng J, et al. Transforming growth factor beta1 signal is crucial for dedifferentiation of cancer cells to cancer stem cells in osteosarcoma. Stem Cells 2013;31:433-46.
31. Clarke MF, Dick JE, Dirks PB, et al. Cancer stem cells-perspectives on current status and future directions: AACR Workshop on cancer stem cells. Cancer Res 2006;66:9339-44.
32. Sun S, Wang Z. Head neck squamous cell carcinoma c-Met (1) cells display cancer stem cell properties and are responsible for cisplatinresistance and metastasis. Int J Cancer 2011;129:2337-48.
33. Lou H, Dean M. Targeted therapy for cancer stem cells: the patched pathway and ABC transporters. Oncogene 2007;26:1357-60.
34. Tang C, Ang BT, Pervaiz S. Cancer stem cell: target for anti-cancer therapy. FASEB J 2007;21:3777-85.
35. Frank NY, Schatton T, Frank MH. The therapeutic promise of the cancer stem cell concept. J Clin Invest 2010;120:41-50.
36. Singh AK, Arya RK, Maheshwari S, et al. Tumor heterogeneity and cancer stem cell paradigm: updates in concept, controversies and clinical relevance. Int J Cancer, in press.
37. Ottinger S, Kloppel A, Rausch V, et al. Targeting of pancreatic and prostate cancer stem cell characteristics by Crambe crambe marine sponge extract. Int J Cancer 2012;130:1671-81.
38. Wen J, Li H, Tao W, et al. High throughput quantitative reverse transcription PCR assays revealing over-expression of cancer testis antigen genes in multiple myeloma stem cell-like side population cells. Br J Haematol, in press.
39. Chaffer CL, Brueckmann I, Scheel C, et al. Normal and neoplastic nonstem cells can spontaneously convert to a stem-like state. Proc Natl Acad Sci USA 2011;108:7950-5.
40. Anderson KC, Carrasco RD. Pathogenesis of myeloma. Annu Rev Pathol 2011;6:249-74.
41. Liu D, Lin P, Hu Y, et al. Immunophenotypic heterogeneity of normal plasma cells: comparison with minimal residual plasma cell myeloma. J Clin Pathol 2012;65:823-9.
42. Heddleston JM, Li Z, Lathia JD, et al. Hypoxia inducible factors in cancer stem cells. Br J Cancer 2010;102:789-95.
43. Keith B, Simon MC. Hypoxia-inducible factors, stem cells, and cancer. Cell 2007;129:465-72.
44. Mazumdar J, Dondeti V, Simon MC. Hypoxiainducible factors in stem cells and cancer. J Cell Mol Med 2009;13:4319-28.
45. Jakowlew SB. Transforming growth factor-beta in cancer and metastasis. Cancer Metastasis Rev 2006;25:435-57.
46. Dong M, Blobe GC. Role of transforming growth factor-beta in hematologic malignancies. Blood 2006;107:4589-96.
47. Gupta PB, Fillmore CM, Jiang G, et al. Stochastic state transitions give rise to phenotypic equilibrium in populations of cancer cells. Cell 2011;146:633-44.
48. Visvader JE, Lindeman GJ. Cancer stem cells: current status and evolving complexities. Cell Stem Cell 2012;10:717-28.